2017年ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS稳定缺血性心脏病血运重建适宜使用标准:美国心脏病学会适宜使用标准工作组、美国胸外科协会、美国心脏协会、美国超声心动图学会、美国核心脏病学会、心血管造影与介入学会、心血管计算机断层扫描学会、胸外科医师学会报告
该文件为稳定缺血性心脏病(SIHD)血运重建适宜使用标准(AUC)的更新版,由多学会联合制定,将SIHD与急性冠脉综合征的AUC分开。独立评分小组对模拟日常实践的临床场景按1至9分评分,7至9分为适宜,1至3分为很少适宜,4至6分为可能适宜。高症状负担、高危特征、高冠脉疾病负担及接受抗心绞痛治疗者血运重建被评为适宜。
要点
- 7至9分表示血运重建适宜,1至3分为很少适宜,4至6分为可能适宜。
- 高症状负担、高危特征、高冠脉疾病负担及接受抗心绞痛治疗者被评为适宜。
- 新增肾移植前或经导管瓣膜治疗前血运重建适宜性的评分场景。
核心结论
- 高症状负担、高危特征、高冠脉疾病负担及接受抗心绞痛治疗的临床场景中,血运重建被评为适宜。
研究设计与样本
- 由美国心脏病学会等多个学会联合完成的2部分修订中的SIHD部分,采用与初版相似但纳入AUC方法学近期修改(最显著为适宜使用分类术语的变更)的方法学。
- 由独立的评分小组对模拟日常实践的临床场景按1至9分评分。
主要发现
- 临床场景包含症状状态、无创检查评估的风险水平、冠脉疾病负担,部分场景还包含血流储备分数检查、糖尿病有无及SYNTAX评分。
- 7至9分表示血运重建对该临床场景为适宜,1至3分为很少适宜,4至6分为可能适宜。
- 高症状负担、高危特征、高冠脉疾病负担及接受抗心绞痛治疗的场景中血运重建被评为适宜。
- 新增肾移植前或经导管瓣膜治疗前血运重建适宜性的评分场景。
关键数值与推荐
- 评分7至9分:血运重建被认为适宜。
- 评分1至3分:血运重建被认为很少适宜。
- 评分4至6分:冠状动脉血运重建可能适宜。
临床怎么用
- AUC的主要目标是提供评估实践模式的框架,以期改善医师决策。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The American College of Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, and American Association for Thoracic Surgery, along with key specialty and subspecialty societies, have completed a 2-part revision of the appropriate use criteria (AUC) for coronary revascularization. In prior coronary revascularization AUC documents, indications for revascularization in acute coronary syndromes and stable ischemic heart disease (SIHD) were combined into 1 document. To address the expanding clinical indications for coronary revascularization, and to align the subject matter with the most current American College of Cardiology/American Heart Association guidelines, the new AUC for coronary artery revascularization were separated into 2 documents addressing SIHD and acute coronary syndromes individually. This document presents the AUC for SIHD.Clinical scenarios were developed to mimic patient presentations encountered in everyday practice. These scenarios included information on symptom status; risk level as assessed by noninvasive testing; coronary disease burden; and, in some scenarios, fractional flow reserve testing, presence or absence of diabetes, and SYNTAX score. This update provides a reassessment of clinical scenarios that the writing group felt were affected by significant changes in the medical literature or gaps from prior criteria. The methodology used in this update is similar to the initial document but employs the recent modifications in the methods for developing AUC, most notably, alterations in the nomenclature for appropriate use categorization.A separate, independent rating panel scored the clinical scenarios on a scale of 1 to 9. Scores of 7 to 9 indicate that revascularization is considered appropriate for the clinical scenario presented. Scores of 1 to 3 indicate that revascularization is considered rarely appropriate for the clinical scenario, whereas scores in the mid-range of 4 to 6 indicate that coronary revascularization may be appropriate for the clinical scenario.As seen with the prior coronary revascularization AUC, revascularization in clinical scenarios with high symptom burden, high-risk features, and high coronary disease burden, as well as in patients receiving antianginal therapy, are deemed appropriate. Additionally, scenarios assessing the appropriateness of revascularization before kidney transplantation or transcatheter valve therapy are now rated. The primary objective of the AUC is to provide a framework for the assessment of practice patterns that will hopefully improve physician decision making.
引用
- Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. J Nucl Cardiol. 2017. PMID: 28608183. doi:10.1007/s12350-017-0917-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。